Advancements in Renal Cell Carcinoma Treatments

This chapter explores the latest findings from the ASCO Genitourinary symposium regarding renal cell carcinoma treatments. It highlights the shift from traditional therapies to the promising results of the pembrolizumab and axitinib combination, including improvements in survival rates and response, while also addressing treatment-related toxicities.